SHIM
ORIC icon

Stone House Investment Management’s Oric Pharmaceuticals ORIC Stock Holding History

Stone House Investment Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195 Buy
+18
New +$163 ﹤0.01% 1207

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stone House Investment Management's ORIC Position: Q2 2026 in Review

Stone House Investment Management opened a new position in Oric Pharmaceuticals (ORIC) in Q2 2026: 18 shares worth $195. The stake represents ﹤0.01% of the portfolio and ranks #1207 among its holdings.

180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Stone House Investment Management held 18 shares of Oric Pharmaceuticals worth $195 as of Q2 2026.
  • Oric Pharmaceuticals was a new Stone House Investment Management position in Q2 2026.
  • Oric Pharmaceuticals made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #1207 holding.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.